Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, has unveiled Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®—the world’s first nebulized, fixed-dose triple therapy for Chronic Obstructive Pulmonary Disease (COPD). This breakthrough marks a major leap forward in respiratory treatment and reinforces Glenmark’s leadership in COPD innovation.
The new Smartules® combine three well-established COPD medications—Glycopyrronium, Formoterol, and Budesonide—into a single nebulized formulation. This fixed-dose combination is designed to enhance lung function, reduce airway inflammation, and improve daily symptom management. According to Glenmark, the therapy simplifies treatment for patients who struggle with Metered Dose Inhalers (MDIs) or Dry Powder Inhalers (DPIs), providing a more convenient and user-friendly alternative.
By delivering all three drugs through a nebulizer, the therapy eliminates the need for multiple devices and complex inhalation techniques. Glenmark highlighted that this approach could redefine the standard of care, especially for moderate to severe COPD patients who need consistent and dependable medication delivery.
Read More